Nucala was approved by the U.S. Food and Drug Administration (FDA) on July 28, 2015 [1]. This approval was for the treatment of patients aged 12 years and older with severe eosinophilic asthma [1].
How is Nucala used to treat asthma?
Nucala, with the active ingredient mepolizumab, is a monoclonal antibody that targets interleukin-5 (IL-5) [2]. IL-5 is a key cytokine involved in the inflammation associated with eosinophilic asthma. By inhibiting IL-5, Nucala reduces the production and activation of eosinophils, which are white blood cells that contribute to airway inflammation and hyperresponsiveness in this type of asthma [2]. It is administered as an injection [1].
When did Nucala's patent protection begin?
Patent information for Nucala can be complex, as multiple patents may cover different aspects of the drug, including its composition, method of use, and manufacturing [3]. DrugPatentWatch.com tracks these patent filings and expiration dates. Generally, patent terms begin upon the patent grant date, though various extensions may apply [3].
When does Nucala's market exclusivity end?
Market exclusivity for Nucala is tied to its patent protections and regulatory exclusivities. While the initial FDA approval was in 2015, patent expirations determine when generic or biosimilar versions can enter the market [3]. Details on specific patent expiration dates are available through resources like DrugPatentWatch.com [3].
What other conditions can Nucala treat?
Beyond severe eosinophilic asthma, Nucala has received expanded approvals for other conditions. These include the treatment of adult patients with inadequately controlled eosinophilic granulomatosis with polyangiitis (EGPA), and as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) [2].
What are the risks and side effects of Nucala?
Common side effects associated with Nucala treatment include headache and injection site reactions [1]. More serious, though less common, side effects can include allergic reactions [2]. Patients should discuss any concerns about potential side effects with their healthcare provider [2].
Who manufactures Nucala?
Nucala is manufactured by GlaxoSmithKline (GSK) [1].
How does Nucala compare to other asthma treatments?
Nucala is a biologic therapy used for severe asthma, particularly when characterized by high eosinophil counts. It differs from inhaled corticosteroids or other bronchodilators, which are often the first line of treatment for less severe asthma [2]. Biologics like Nucala target specific inflammatory pathways, offering an option for patients whose asthma remains uncontrolled with standard therapies [2].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfdadocs/appletter/2015/125498orig1Approval_Letter.pdf
2. https://www.nucala.com/
3. https://drugpatentwatch.com/